Albert Cheung, MD
Ophthalmology · Norfolk, VANPI 1134482466
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Sight Sciences, Inc. accounts for 62.1% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $8,451, 4.2 times the $2,011 reported in 2019. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $121.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$14K
- Tarsus Pharmaceuticals, Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Mallinckrodt Hospital Products Inc.$840
- Dompe US, Inc.$527
- Alcon$458
- plus $3K from 23 others
What the payments were for
- Consulting fees$8,85039%
- Speaking & faculty fees$8,25036%
- Grants$280%
- Food & beverage$5,43424%
- Education$1341%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 17 | $14,099 |
| Tarsus Pharmaceuticals, Inc. | 11 | $2,556 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $1,519 |
| Mallinckrodt Hospital Products Inc. | 28 | $840 |
| Dompe US, Inc. | 15 | $527 |
| Alcon | 15 | $458 |
| Bausch & Lomb Americas Inc. | 17 | $379 |
| Sun Pharmaceutical Industries Inc. | 17 | $371 |
| Glaukos Corporation | 3 | $347 |
| Biotissue Holdings Inc. | 10 | $248 |
| Alcon Research LLC | 2 | $189 |
| Novartis | 9 | $180 |
| Oyster Point Pharma, Inc. | 6 | $140 |
| NEW World Medical,inc. | 1 | $103 |
| Amgen(2 entities) | 5 | $101 |
| AbbVie | 5 | $96 |
| Rayner Intraocular Lenses Limited | 3 | $94 |
| Harrow Eye, LLC | 4 | $92 |
| Lombart Brothers, Inc. | 2 | $83 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| Tearlab Corp | 1 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Omeros Corporation | 2 | $31 |
| Aerie Pharmaceuticals, Inc. | 2 | $31 |
| Shire North American Group Inc | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Thea Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEARCARE SYSTEM$5,467
- OMNI(R) SURGICAL SYSTEM (US)$4,500
- SION SURGICAL INSTRUMENT$4,500
- TearCare SmartLid$3,893
- TEARCARE(TM) (2.2) SYSTEM KIT$3,893
- Tecnis Symfony IOL$1,500
- KXL System$322
- Clareon$153
- Photrexa Viscous and Photrexa$151
- Precision 1$146
- ENVISTA ENVY$112
- ACTHAR$106
How this compares
$22,716 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 36 | $1,005,007 |
| RestasisCyclosporine | 63 | $84,889 |
| MieboPerfluorohexyloctane/Pf | 42 | $36,919 |
| Prednisolone Acetate | 371 | $20,141 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $17,944 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $17,258 |
| XiidraLifitegrast | 18 | $15,795 |
| Cyclosporine | 26 | $13,876 |
| RhopressaNetarsudil Mesylate | 15 | $8,862 |
| Difluprednate | 93 | $8,158 |
| Alphagan PBrimonidine Tartrate | 16 | $6,767 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $5,875 |
| MoxifloxacinMoxifloxacin Hcl | 172 | $5,707 |
| ValacyclovirValacyclovir Hcl | 113 | $5,355 |
| Ketorolac Tromethamine | 205 | $4,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $527 | $1,005,00736 claims |
| AbbVieRestasis, Combigan, Alphagan P | $96 | $108,914128 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $379 | $52,71460 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $31 | $26,80649 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $19 | $6,90237 claims |
| AlconSimbrinza | $458 | $5,87525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.